Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical Trials

Ann-Lii Cheng, MD, PhD
Published: Saturday, Sep 15, 2018



Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.

In the past, tumor heterogeneity was not a large consideration for clinicians using molecularly targeted therapy in HCC, because driver mutations could not be identified. However, in the new era of immunotherapy, tumor heterogeneity presents a larger issue.

For the future of this landscape, researchers will not only need to understand heterogeneity in the cancer genome, but also heterogeneity among immune cells. New areas of research include identification of more specific T cells relevant to the treatment of HCC, as well as the mutation type that will be the responsive to immunotherapy.

In this new field of inquiry, it will be increasingly important to explore more specific biomarkers that can aid in patient selection and follow-up for both clinical trials and clinical management.

View more from the 2018 International Liver Cancer Association Annual Conference

Brought to you in part by Eisai


Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.

In the past, tumor heterogeneity was not a large consideration for clinicians using molecularly targeted therapy in HCC, because driver mutations could not be identified. However, in the new era of immunotherapy, tumor heterogeneity presents a larger issue.

For the future of this landscape, researchers will not only need to understand heterogeneity in the cancer genome, but also heterogeneity among immune cells. New areas of research include identification of more specific T cells relevant to the treatment of HCC, as well as the mutation type that will be the responsive to immunotherapy.

In this new field of inquiry, it will be increasingly important to explore more specific biomarkers that can aid in patient selection and follow-up for both clinical trials and clinical management.

View more from the 2018 International Liver Cancer Association Annual Conference

Brought to you in part by Eisai

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x